Tag: nontuberculous mycobacterial infection market scope

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Nontuberculous Mycobacterial Infection Market from 2024 to 2025?#_x000D_

There has been a robust expansion in the nontuberculous mycobacterial infection market size in the past few years. It is expected to increase from $14.25 billion in 2024 to $15.11 billion in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors such as enhanced diagnostics, an older population, awareness of cystic fibrosis, and immunosuppressive drugs have contributed to growth during the historic period._x000D_

_x000D_

#What Is the Projected Market Size of the Nontuberculous Mycobacterial Infection Market?#_x000D_

In the upcoming years, the nontuberculous mycobacterial infection market is projected to witness substantial growth and reach a valuation of $19.57 billion in 2029, expanding at a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the forecast period include the advancement of antimicrobial drugs, elevated awareness of NTM, progress in genetic research, and the rise of telehealth and remote monitoring. Key trends expected during this period encompass tailored treatment, regulatory emphasis, integrated therapies, and the use of digital health tools._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp_x000D_

_x000D_

#Who are the Major Competitors in the Nontuberculous Mycobacterial Infection Market Outlook?#_x000D_

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC._x000D_

_x000D_

#What Is Fueling Growth in the Nontuberculous Mycobacterial Infection Market?#_x000D_

The growing incidence of chronic obstructive pulmonary disease (COPD) is projected to boost the expansion of the nontuberculous mycobacterial infection market. Chronic obstructive pulmonary disease (COPD) is a persistent respiratory disorder marked by continuous and often worsening limitation of airflow in the lungs. Patients with COPD who develop nontuberculous mycobacterial (NTM) infections are found to experience substantial deterioration of forced expiratory volume in a second (FEV1) with a higher-exacerbation rate. COPD may impair the immune system and cause damage to the lung tissues, thereby making the lungs more susceptible to NTM bacterial infection. For example, in March 2023, a report published by The Scottish Public Health Observatory (ScotPHO), indicated that COPD rates started to surge between 2021 and 2022, with an increase in males from 83.2 to 97.6 per 100,000 people, while in females, it went up from 72.6 to 97.3. Hence, the escalating instances of chronic obstructive pulmonary disease (COPD) is sparking the expansion of the nontuberculous mycobacterial infection market. Additionally, the nontuberculous mycobacterial infection market can be further propelled by the increasing instances of infectious diseases. Infectious diseases, caused by harmful microorganisms including bacteria, viruses, fungi, and parasites, can spread from one person to another, manifesting diverse symptoms and health complications. The growing prevalence of infectious diseases, including those leading to Nontuberculous Mycobacterial (NTM) infections, could potentially fuel the NTM infection market expansion. It could elevate the awareness towards these infections, encourage more regular screening and early detection, increase the endeavour towards R&D for NTM treatments, and elevate the demand for therapies targeting NTM pathogens due to an intensified focus on infectious diseases in healthcare. For example, in November 2024, according to UNICEF, pneumonia was identified as the major infectious disease causing death in more than 700,000 children per year, amounting to approximately 2,000 children every day. Hence, the growing prevalence of infectious diseases is contributing to the growth of the nontuberculous mycobacterial infection market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp_x000D_

_x000D_

#Which Nontuberculous Mycobacterial Infection Market Segments Are Growing the Fastest?#_x000D_

The nontuberculous mycobacterial infection market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes_x000D_

2) By Route Of Administration: Oral, Parenteral, Other Routes_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Macrolides: Azithromycin, Clarithromycin_x000D_

2) By Rifampin: Rifampin, Rifabutin_x000D_

3) By Aminoglycoside: Amikacin, Streptomycin_x000D_

4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid_x000D_

_x000D_

#Which Industry Trends Are Shaping the Future of the Nontuberculous Mycobacterial Infection Market?#_x000D_

Leading firms in the nontuberculous mycobacterial infection market are employing new approval methods for treatments, such as the fast track designation for drug approval, to maintain their market standing. The Fast Track designation offered by the FDA is a procedure made to accelerate the production and examination of drugs for severe conditions that do not yet have a medical solution. For example, in July 2022, the Food and Drug Administration, an American federal agency, awarded NUZYRA with Fast Track Designation to manage nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), an innovative broad-range antibiotic, was developed to fight serious bacterial infections, including those caused by resistant strains. This designation expedites the development and review of NUZYRA antibiotic, addressing substantial medical needs that are currently unmet._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report_x000D_

_x000D_

#Which Countries Are Leading the Nontuberculous Mycobacterial Infection Market?#_x000D_

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the nontuberculous mycobacterial infection market, and how is it changing globally?_x000D_

2. Who are the major companies in the nontuberculous mycobacterial infection market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the nontuberculous mycobacterial infection market right now?_x000D_

4. Which products or customer segments are growing the most in the nontuberculous mycobacterial infection market?_x000D_

5. What factors are helping or slowing down the growth of the nontuberculous mycobacterial infection market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the nontuberculous mycobacterial infection industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Nontuberculous Mycobacterial Infection Market Size From 2025 to 2034?

The market size for nontuberculous mycobacterial infection has seen robust growth in recent times. The growth is projected to escalate from $14.25 billion in 2024 to $15.11 billion in 2025, marking a compound annual growth rate (CAGR) of 6.0%. The progress during the historic period can be ascribed to advancements in diagnostics, an increasing aging population, heightened awareness of cystic fibrosis, and the use of immunosuppressive drugs.

The market for nontuberculous mycobacterial infection is predicted to experience substantial growth in the coming years. It is anticipated to reach a value of $19.57 billion by 2029, with a compound annual growth rate of 6.7%. Elements contributing to this growth throughout the projected period include the development of antimicrobial drugs, increasing awareness about ntm, advancements in genetic research, and the rise of telehealth and remote monitoring. Key trends for this period encompass personalized treatment plans, regulatory focus, combination therapies, as well as digital health tools.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Nontuberculous Mycobacterial Infection Market?

The increasing incidence of chronic obstructive pulmonary disease (COPD) is anticipated to drive the nontuberculous mycobacterial infection market’s expansion. COPD is a long-term respiratory disease marked by continuous and often increasing limitations on airflow within the lungs. The damage caused to the lung tissue by COPD and the weakening of the immune system make it simpler for nontuberculous mycobacterial (NTM) infections to invade the lungs. Notably, patients with COPD who also have NTM infections present a more notable decrease in their forced expiratory volume in one second (FEV1) and a higher rate of exacerbation. As highlighted by The Scottish Public Health Observatory (ScotPHO) in March 2023, COPD rates have begun to increase between 2021 and 2022, with male rates escalating from 83.2 to 97.6 per 100,000 individuals, and female rates increasing from 72.6 to 97.3. Consequently, the rising rate of chronic obstructive pulmonary disease (COPD) is propelling the nontuberculous mycobacterial infection market. An upsurge in the prevalence of infectious diseases is predicted to fuel the growth of the nontuberculous mycobacterial infection market. Infectious diseases are pathological conditions provoked by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, which can transmit from one person to another. Notably, conditions that could potentially lead to Nontuberculous Mycobacterial (NTM) infections also contribute to the rising prevalence of infectious diseases. This spurs the growth of the NTM infection market by increasing awareness, encouraging more frequent diagnostic procedures and early detection, amplifying research and development endeavors for NTM treatments, and creating larger demand for therapies aimed at NTM pathogens due to increased emphasis on infectious diseases within healthcare. According to UNICEF in November 2024, pneumonia was the top infectious disease causing over 700,000 child deaths per year, corresponding to around 2,000 children each day. Hence, the heightened incidence of infectious diseases boosts the growth of the nontuberculous mycobacterial infection market.

Which Key Market Segments Comprise the Nontuberculous Mycobacterial Infection Market and Drive Its Revenue Growth?

The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin

2) By Rifampin: Rifampin, Rifabutin

3) By Aminoglycoside: Amikacin, Streptomycin

4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

Which Areas Are Leading Regions in the Nontuberculous Mycobacterial Infection Market Expansion Across the Globe?

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Key Market Trends in theNontuberculous Mycobacterial Infection Market Over the Coming Years?

Primary organizations in the nontuberculous mycobacterial infection market have adopted new methodologies for treatment approval, such as the Fast Track designation, to maintain their market presence. The FDA has set up a process known as Fast Track designation to hasten the growth and evaluation of medications for serious conditions lacking sufficient medical solutions. For instance, in July 2022, the Food and Drug Administration, a government agency in the U.S., authorized NUZYRA with Fast Track Designation to cure nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), a unique broad-spectrum antibiotic, was developed to fight severe bacterial infections, including those triggered by resistant varieties. This designation ensures a swift advancement and assessment process for NUZYRA antibiotic in order to address significant unmet medical needs.

View the full report here:

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

How Is the Nontuberculous Mycobacterial Infection Market Conceptually Defined?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Nontuberculous Mycobacterial Infection Market From 2025 to 2034?

The size of the nontuberculous mycobacterial infection market has experienced robust growth over the past few years. It is set to increase from $14.25 billion in 2024 to $15.11 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The historical growth of this market can be tied to enhanced diagnostic procedures, an aging demographic, increased awareness of cystic fibrosis, and the use of immunosuppressive drugs.

In the coming years, the market size for nontuberculous mycobacterial infection is projected to witness substantial growth. Forecasts predict it will expand to $19.57 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. The expansion during the projected period can be linked to elements such as the development of antimicrobial drugs, increased awareness of ntm, advancements in genetic studies, telehealth and remote examination. The prime trends for the projected period comprise personalized therapy, emphasis on regulations, combined therapies and digital health apparatus.

What Key Drivers Are Accelerating the Growth of the Nontuberculous Mycobacterial Infection Market During the Forecast Period?

The escalating incidence of chronic obstructive pulmonary disease (COPD) is predicted to spur the expansion of the nontuberculous mycobacterial infection market. COPD is a long-term respiratory ailment marked by continuous and often worsening airflow obstruction in the lungs. Patients with COPD suffering from nontuberculous mycobacterial (NTM) infections encounter a more considerable decrease in forced expiratory volume in one second (FEV1) and a higher rate of exacerbation. COPD can compromise the immune system and harm lung tissue, making it more susceptible to NTM bacterial infections. For instance, according to a report issued by The Scottish Public Health Observatory (ScotPHO) in March 2023, COPD rates started to escalate from 2021 to 2022. The rate for men rose from 83.2 to 97.6 per 100,000 individuals, while for women, the rate increased from 72.6 to 97.3. Thus, the escalating prevalence of COPD is propelling the expansion of the nontuberculous mycobacterial infection market. A rise in the prevalence of infectious diseases is projected to boost the nontuberculous mycobacterial infection market’s growth. Infectious diseases, triggered by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, can spread from one person to another, causing various symptoms and health concerns. The growing prevalence of infectious diseases, including conditions that can result in Nontuberculous Mycobacterial (NTM) infections, can potentially drive the nontuberculous mycobacterial infection market’s growth, by promoting awareness about these infections. This can lead to more widespread diagnostic testing and early detection, heightened research and development concerning NTM therapies, and increased demand for treatments targeting NTM pathogens due to a more significant healthcare focus on infectious diseases. For example, in November 2024, according to the United Nations International Children’s Emergency Fund (UNICEF), pneumonia was identified as the most prevalent infectious disease, causing over 700,000 children’s deaths every year, approximately 2,000 children daily. Hence, the growing prevalence of infectious diseases propels the nontuberculous mycobacterial infection market’s growth.

Request Your Free Nontuberculous Mycobacterial Infection Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

What Are the Key Industry Players Leading the Charge in the Nontuberculous Mycobacterial Infection Market’s Growth?

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Nontuberculous Mycobacterial Infection Market?

Primary businesses in the nontuberculous mycobacterial infection market are embracing innovative treatment approval methods, including fast track designation for pharmaceutical approval, to maintain their market dominance. The FDA’s Fast Track designation is a procedure aimed at rapidly advancing the development and assessment of medications for serious health conditions that lack sufficient medical solutions. For example, the US-based federal entity, the Food and Drug Administration, awarded NUZYRA Fast Track Designation in July 2022 for treating (NTM) lung disease provoked by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), a new broad-spectrum antibiotic, was created to fight against severe bacterial infections, including those brought about by resistant strains. This designation accelerates the development and review processes for the NUZYRA antibiotic to address significant unmet medical demands.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

How Are the Key Segments of the Nontuberculous Mycobacterial Infection Market Driving Opportunities and Innovations?

The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin

2) By Rifampin: Rifampin, Rifabutin

3) By Aminoglycoside: Amikacin, Streptomycin

4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

What Regions Are Influencing the Dynamics of the Nontuberculous Mycobacterial Infection Market?

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Scope and Reach of the Nontuberculous Mycobacterial Infection Market Defined?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

Browse Through More Similar Reports By The Business Research Company:

Cough And Cold Preparations Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

Respiratory Monitoring Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-monitoring-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: